MRC Mitochondrial Biology Unit |

mrc_mbu_cambridge_rgb.png

The strategic mission of the MBU is to understand mitochondrial biology in health and disease, and to exploit this understanding to develop new therapies and improve human health.

New research uncovers a novel family of phospholipid remodelling enzymes

6 March 2025

Phospholipids, the fundamental building blocks of cellular membranes, are continuously remodelled to ensure membrane integrity and function. A new study from the lab of Dr Kasparas Petkevicius at the MRC Mitochondrial Biology Unit, published in Science Advances , demonstrates that TRAM-LAG1-CLN8 (TLC) family proteins...

Abigail Giles receives The Richard J Bing Award for Young Investigators

2 June 2025

At the recent World Congress of the International Society for Heart Research , held in Japan, Abigail Giles was awarded The Richard J Bing Award for Young Investigators . Abigail studied for her PhD at the MBU, funded by the NIH Oxford-Cambridge Partnership Program, spending her time split between Cambridge and the...

Mike Murphy elected as a member of Academia Europaea

19 May 2025

Congratulations to Professor Mike Murphy , who has been elected as a member of Academia Europaea : The Academy of Europe. The object of Academia Europaea is the advancement and propagation of excellence in scholarship in the humanities, law, the economic, social, and political sciences, mathematics, medicine, and all...

Structure of the mitochondrial pyruvate carrier visualised by cryo-electron microscopy

18 April 2025

Fifty years since its discovery, scientists in the laboratory of Professor Edmund Kunji have finally worked out how a molecular machine found in mitochondria allows us to make the fuel we need from sugars, a process vital to all life on Earth. In collaboration with the groups of Professors Vanessa Leone at the Medical...

Pretzel Therapeutics, an MBU spin-out company, launches Phase 1 clinical study

4 April 2025

Pretzel Therapeutics has announced the initiation of recruitment for a Phase 1 clinical study of PX578, the lead therapeutic in its bioenergetics restoration phase. The randomized, double-blind, placebo-controlled study is designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending...

Cambridge Festival 2025 - Biomedical Campus Day

26 March 2025

On 22 March, members of the MBU enjoyed a very successful event at the Cambridge Festival Biomedical Campus Day. Our scientists showcased the Unit's research through the use of games and activities aimed audiences of all ages. The event was hosted at the Cambridge Academy for Science and Technology , where we shared a...

Batten Disease Global Research Initiative Grant for Kasparas Petkevicius

19 March 2025

Congratulations to Kasparas Petkevicius , who has been awarded a grant of $50,000 from the Batten Disease Global Research Initiative , which will fund a research project “Exploring the efficacy of bis(monoacylglycero)phosphate synthesis pathway intermediates in treating CLN8 Batten disease in preclinical models.” Batten...

MRC Mitochondrial Biology Unit

mrc_mbu_cambridge_rgb.png

mrc_mbu_cambridge_rgb.png

The strategic mission of the MBU is to understand mitochondrial biology in health and disease, and to exploit this understanding to develop new therapies and improve human health.

New research uncovers a novel family of phospholipid remodelling enzymes

Abigail Giles receives The Richard J Bing Award for Young Investigators

Mike Murphy elected as a member of Academia Europaea

Structure of the mitochondrial pyruvate carrier visualised by cryo-electron microscopy

Pretzel Therapeutics, an MBU spin-out company, launches Phase 1 clinical study

Cambridge Festival 2025 - Biomedical Campus Day

Batten Disease Global Research Initiative Grant for Kasparas Petkevicius

bluesky-web.png

Interested in doing a PhD at the MBU?

Seminars and Events

CONTACT US

INFORMATION COMPLIANCE

FIND US ON SOCIAL MEDIA

INSTITUTIONAL LINKS

Study at Cambridge

About the University

Research at Cambridge